Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma
Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized trial showed. After 4 years of follow-up, neither the median PFS nor the 3-year PFS differed significantly among four treatment groups who received lenalidomide (Revlimid) and bortezomib (Velcade) plus dexamethasone […]